- Home
- ROOT vs OMER Comparison
ROOT vs OMER Comparison
Compare ROOT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | OMER |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 804.6M | 821.7M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ROOT | OMER |
|---|---|---|
| Price | $48.22 | $11.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $108.40 | $32.50 |
| AVG Volume (30 Days) | 365.8K | ★ 827.4K |
| Earning Date | 05-28-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.96 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $1,517,100,000.00 | $29,868,000.00 |
| Revenue This Year | $10.08 | N/A |
| Revenue Next Year | $12.63 | N/A |
| P/E Ratio | $20.39 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $46.63 | $2.95 |
| 52 Week High | $181.14 | $17.65 |
Technical Indicators
Market Signals| Indicator | ROOT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 33.14 | 46.50 |
| Support Level | N/A | $10.82 |
| Resistance Level | $88.63 | $11.90 |
| Average True Range (ATR) | 3.47 | 0.52 |
| MACD | -0.73 | 0.01 |
| Stochastic Oscillator | 10.82 | 28.68 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.